Advertisement
| fas full analysis set: Severe Asthma Kian Fan Chung, Elliot Israel, Peter G. Gibson, 2019-06-01 Severe asthma is a form of asthma that responds poorly to currently available medication, and its patients represent those with greatest unmet needs. In the last 10 years, substantial progress has been made in terms of understanding some of the mechanisms that drive severe asthma; there have also been concomitant advances in the recognition of specific molecular phenotypes. This ERS Monograph covers all aspects of severe asthma – epidemiology, diagnosis, mechanisms, treatment and management – but has a particular focus on recent understanding of mechanistic heterogeneity based on an analytic approach using various ‘omics platforms applied to clinically well-defined asthma cohorts. How these advances have led to improved management targets is also emphasised. This book brings together the clinical and scientific expertise of those from around the world who are collaborating to solve the problem of severe asthma. |
| fas full analysis set: The Prevention and Treatment of Missing Data in Clinical Trials National Research Council, Division of Behavioral and Social Sciences and Education, Committee on National Statistics, Panel on Handling Missing Data in Clinical Trials, 2010-12-21 Randomized clinical trials are the primary tool for evaluating new medical interventions. Randomization provides for a fair comparison between treatment and control groups, balancing out, on average, distributions of known and unknown factors among the participants. Unfortunately, these studies often lack a substantial percentage of data. This missing data reduces the benefit provided by the randomization and introduces potential biases in the comparison of the treatment groups. Missing data can arise for a variety of reasons, including the inability or unwillingness of participants to meet appointments for evaluation. And in some studies, some or all of data collection ceases when participants discontinue study treatment. Existing guidelines for the design and conduct of clinical trials, and the analysis of the resulting data, provide only limited advice on how to handle missing data. Thus, approaches to the analysis of data with an appreciable amount of missing values tend to be ad hoc and variable. The Prevention and Treatment of Missing Data in Clinical Trials concludes that a more principled approach to design and analysis in the presence of missing data is both needed and possible. Such an approach needs to focus on two critical elements: (1) careful design and conduct to limit the amount and impact of missing data and (2) analysis that makes full use of information on all randomized participants and is based on careful attention to the assumptions about the nature of the missing data underlying estimates of treatment effects. In addition to the highest priority recommendations, the book offers more detailed recommendations on the conduct of clinical trials and techniques for analysis of trial data. |
| fas full analysis set: Acute and Hereditary Coagulation Disorders Felix Carl Fabian Schmitt, Herbert Schöchl , Wolfgang Miesbach, 2024-11-01 Coagulation disorders can have a variety of causes and may lead to either an increased risk of excessive bleeding or an increased risk of thromboembolic events. Both types of coagulation disorders can be life-threatening and require immediate therapy. Major bleeding is often triggered by an acute cause, such as severe trauma or peripartum hemorrhage (PPH) . The high rate of pre-existing intake of anticoagulants, such as DOACS or Vitamin-K antagonists, can also induce or even aggravate bleeding events, for example in cerebral hemorrhage or traumatic brain injury (TBI). Hereditary causes, such as the congenital Factor XIII deficiency or hemophilia, can also trigger a clinically relevant hemorrhage however, hereditary coagulation disorders are more often associated with thromboembolic events. |
| fas full analysis set: Statistical Methods For Biomedical Research Ji-qian Fang, 2021-03-18 This book consists of four parts with 32 chapters adapted for four short courses, from the basic to the advanced levels of medical statistics (biostatistics), ideal for biomedical students. Part 1 is a compulsory course of Basic Statistics with descriptive statistics, parameter estimation and hypothesis test, simple correlation and regression. Part 2 is a selective course on Study Design and Implementation with sampling survey, interventional study, observational study, diagnosis study, data sorting and article writing. Part 3 is a specially curated course of Multivariate Analyses with complex analyses of variance, variety of regressions and classical multivariate analyses. Part 4 is a seminar course on Introduction to Advanced Statistical Methods with meta-analysis, time series, item response theory, structure equation model, multi-level model, bio-informatics, genetic statistics and data mining.The main body of each chapter is followed by five practical sections: Report Writing, Case Discrimination, Computer Experiments, Frequently Asked Questions and Summary, and Practice & Think. Moreover, there are 2 attached Appendices, Appendix A includes Introductions to SPSS, Excel and R respectively, and Appendix B includes all the programs, data and printouts for Computer Experiments in addition to the Tests for Review and the reference answers for Case Discrimination as well as Practice & Think..This book can be used as a textbook for biomedical students at both under- and postgraduate levels. It can also serve as an important guide for researchers, professionals and officers in the biomedical field. |
| fas full analysis set: Registries for Evaluating Patient Outcomes Agency for Healthcare Research and Quality/AHRQ, 2014-04-01 This User’s Guide is intended to support the design, implementation, analysis, interpretation, and quality evaluation of registries created to increase understanding of patient outcomes. For the purposes of this guide, a patient registry is an organized system that uses observational study methods to collect uniform data (clinical and other) to evaluate specified outcomes for a population defined by a particular disease, condition, or exposure, and that serves one or more predetermined scientific, clinical, or policy purposes. A registry database is a file (or files) derived from the registry. Although registries can serve many purposes, this guide focuses on registries created for one or more of the following purposes: to describe the natural history of disease, to determine clinical effectiveness or cost-effectiveness of health care products and services, to measure or monitor safety and harm, and/or to measure quality of care. Registries are classified according to how their populations are defined. For example, product registries include patients who have been exposed to biopharmaceutical products or medical devices. Health services registries consist of patients who have had a common procedure, clinical encounter, or hospitalization. Disease or condition registries are defined by patients having the same diagnosis, such as cystic fibrosis or heart failure. The User’s Guide was created by researchers affiliated with AHRQ’s Effective Health Care Program, particularly those who participated in AHRQ’s DEcIDE (Developing Evidence to Inform Decisions About Effectiveness) program. Chapters were subject to multiple internal and external independent reviews. |
| fas full analysis set: Statistical Thinking for Non-Statisticians in Drug Regulation Richard Kay, 2022-11-29 STATISTICAL THINKING FOR NON-STATISTICIANS IN DRUG REGULATION Statistical methods in the pharmaceutical industry are accepted as a key element in the design and analysis of clinical studies. Increasingly, the medical and scientific community are aligning with the regulatory authorities and recognizing that correct statistical methodology is essential as the basis for valid conclusions. In order for those correct and robust methods to be successfully employed there needs to be effective communication across disciplines at all stages of the planning, conducting, analyzing and reporting of clinical studies associated with the development and evaluation of new drugs and devices. Statistical Thinking for Non-Statisticians in Drug Regulation provides a comprehensive in-depth guide to statistical methodology for pharmaceutical industry professionals, including physicians, investigators, medical science liaisons, clinical research scientists, medical writers, regulatory personnel, statistical programmers, senior data managers and those working in pharmacovigilance. The author’s years of experience and up-to-date familiarity with pharmaceutical regulations and statistical practice within the wider clinical community make this an essential guide for the those working in and with the industry. The third edition of Statistical Thinking for Non-Statisticians in Drug Regulation includes: A detailed new chapter on Estimands in line with the 2019 Addendum to ICH E9 Major new sections on topics including Combining Hierarchical Testing and Alpha Adjustment, Biosimilars, Restricted Mean Survival Time, Composite Endpoints and Cumulative Incidence Functions, Adjusting for Cross-Over in Oncology, Inverse Propensity Score Weighting, and Network Meta-Analysis Updated coverage of many existing topics to reflect new and revised guidance from regulatory authorities and author experience Statistical Thinking for Non-Statisticians in Drug Regulation is a valuable guide for pharmaceutical and medical device industry professionals, as well as statisticians joining the pharmaceutical industry and students and teachers of drug development. |
| fas full analysis set: Understanding Clinical Data Analysis Ton J. Cleophas, Aeilko H. Zwinderman, 2016-08-23 This textbook consists of ten chapters, and is a must-read to all medical and health professionals, who already have basic knowledge of how to analyze their clinical data, but still, wonder, after having done so, why procedures were performed the way they were. The book is also a must-read to those who tend to submerge in the flood of novel statistical methodologies, as communicated in current clinical reports, and scientific meetings. In the past few years, the HOW-SO of current statistical tests has been made much more simple than it was in the past, thanks to the abundance of statistical software programs of an excellent quality. However, the WHY-SO may have been somewhat under-emphasized. For example, why do statistical tests constantly use unfamiliar terms, like probability distributions, hypothesis testing, randomness, normality, scientific rigor, and why are Gaussian curves so hard, and do they make non-mathematicians getting lost all the time? The book will cover the WHY-SOs. |
| fas full analysis set: Handbook Of Medical Statistics Ji-qian Fang, 2017-07-28 This unique volume focuses on the 'tools' of medical statistics. It contains over 500 concepts or methods, all of which are explained very clearly and in detail.Each chapter focuses on a specific field and its applications. There are about 20 items in each chapter with each item independent of one another and explained within one page (plus references). The structure of the book makes it extremely handy for solving targeted problems in this area.As the goal of the book is to encourage students to learn more combinatorics, every effort has been made to provide them with a not only useful, but also enjoyable and engaging reading.This handbook plays the role of 'tutor' or 'advisor' for teaching and further learning. It can also be a useful source for 'MOOC-style teaching'. |
| fas full analysis set: Assessing Physical Fitness Components, Obesity, Motor Skills, Health Outcomes and Academic Performance of Schoolchildren Souhail Hermassi, René Schwesig, El Ghali Bouhafs, Ferman Konukman, Ahmad Salman, 2023-09-13 |
| fas full analysis set: Innovations and Advances in Wound Healing Seung-Kyu Han, 2023-03-27 This book presents state of the art knowledge on new techniques and materials that can improve functional and aesthetic results in wound healing while reducing invasiveness, based on the author's extensive personal experience. The aim is to equip the practitioner with all the information required in order to select a strategy that will accelerate wound healing and minimize both the risk of complications and scar formation after the wound has fully healed. The opening chapters set the stage by providing an overview of wound healing, including brief descriptions of the anatomy of the skin, the wound healing process, and advanced wound dressings. A full description follows of the various methodologies employed in repairing acute wounds with the goal of achieving optimal functional and cosmetic outcomes while utilizing the safest and least invasive method. Treatment protocols that have proven successful in closing nonhealing and/or delayed healing chronic wounds are then presented. In addition, a chapter addresses aesthetic procedures using advanced technology in wound healing. The closing chapter presents author’s experience with the establishment a hospital wound dressing team. The text is supported by 1,411 full color photos. Since the publication of the second edition, there have been many notable advances in wound healing research. The third edition is expanded and updated to reflect the advancements and new information. Key revisions include new chapters and/or sections on recently developed dressings such as a bioelectric dressing, a fluorescence imaging device of bacteria, usefulness of fibrin glue to support wound healing, graft of 3D-printed micronized adipose tissue, significance of skin hydration level for wound healing, novel staged excision technique to reduce scar length, newly developed risk scoring system to predict wound healing outcomes in diabetic patients, expanded coverage of cell therapy, new devices such as extracorporeal shock wave therapy, and automated SVF cell isolation system. |
| fas full analysis set: Clinical trials in drug metabolism and transport: 2022 Yurong Lai, Stanislav Yanev, Zhihao Liu, 2023-11-02 |
| fas full analysis set: Global New Drug Development Jan A. Rosier, Mark A. Martens, Josse R. Thomas, 2014-07-03 The development of new drugs is very complex, costly and risky. Its success is highly dependent on an intense collaboration and interaction between many departments within the drug development organization, external investigators and service providers, in constant dialogue with regulatory authorities, payers, academic experts, clinicians and patient organizations. Within the different phases of the drug life cycle, drug development is by far the most crucial part for the initial and continued success of a drug on the market. This book offers an introduction to the field of drug development with a clear overview of the different processes that lead to a successful new medicine and of the regulatory pathways that are used to launch a new drug that are both safe and efficacious. This is the most comprehensive and detailed book on drug development I have ever read and I feel that it is likely to become a staple of drug development courses, such as those taught at Masters Level in my own University.... I think in the light of increasing integration of company and academic approaches to drug development both sides can read this book... (and, therefore)... this book could not be more timely. —Professor Mike Coleman, University of Aston, UK ( from his review of the final manuscript) |
| fas full analysis set: Reviews of Physiology, Biochemistry and Pharmacology Stine Helene Falsig Pedersen, 2023-01-13 Leading researchers are specially invited to provide a complete understanding of a key topic within the multidisciplinary fields of physiology, biochemistry and pharmacology. In a form immediately useful to scientists, this periodical aims to filter, highlight and review the latest developments in these rapidly advancing fields. |
| fas full analysis set: Evidence-based Clinical Chinese Medicine - Volume 29: Cervical Radiculopathy Claire Shuiqing Zhang, Dihui Zhang, 2021-07-27 This 29th volume of the Evidence-based Clinical Chinese Medicine series aims to provide a multi-faceted 'whole evidence' analysis of the management of cervical radiculopathy in integrative Chinese medicine.Beginning with overviews of how cervical radiculopathy is conceptualised and managed in both conventional medicine and contemporary Chinese medicine, the authors then provide detailed analyses of how cervical radiculopathy was treated with herbal medicine and acupuncture in past eras.In the subsequent chapters, the authors provide a comprehensive review of the current state of the clinical trial evidence for Chinese herbal medicines (Chapter 5), acupuncture (Chapter 7), other Chinese medicine therapies (Chapter 8), and combination Chinese medicine therapies (Chapter 9) in the management of cervical radiculopathy, as well as an analysis and evaluation of the results of these studies from an evidence-based medicine perspective. Chapter 6 provides a review and summary of the experimental evidence for the bioactivity of commonly used Chinese herbs. The outcomes of these analyses are summarised and discussed in Chapter 10. The implications for the clinical practice of Chinese medicine and for future research are also identified.This book can inform clinicians and students in the fields of integrative medicine and Chinese medicine regarding contemporary practice and the current evidence base for a range of Chinese medicine therapies used in the management of Cervical Radiculopathy, including herbal formulas and acupuncture treatments, in order to assist clinicians in making evidence-based decisions in patient care. |
| fas full analysis set: Innovation in Rheumatic Diseases Helena Canhao, Ana Maria Rodrigues, Pedro Oliveira, 2022-02-17 |
| fas full analysis set: Fibrosis in the Respiratory and Digestive Systems Jian Gao, Yang Zhou, Jing Qu, Hong-Long Ji, 2022-05-23 |
| fas full analysis set: Pharyngeal Diseases—Advances in Research and Treatment: 2012 Edition , 2012-12-26 Pharyngeal Diseases—Advances in Research and Treatment: 2012 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Pharyngeal Diseases in a compact format. The editors have built Pharyngeal Diseases—Advances in Research and Treatment: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Pharyngeal Diseases in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Pharyngeal Diseases—Advances in Research and Treatment: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/. |
| fas full analysis set: Acupuncture for pain management Zheng-jie Li, Jian Kong, 2023-07-05 |
| fas full analysis set: Angiotensin-converting Enzyme Inhibitors vs. Angiotensin Receptor Blockers Mukesh Nandave, |
| fas full analysis set: Advanced Statistics in Regulatory Critical Clinical Initiatives Wei Zhang, Fangrong Yan, Feng Chen, Shein-Chung Chow, 2022-05-25 Advanced Statistics in Regulatory Critical Clinical Initiatives is focused on the critical clinical initiatives introduced by the 21st Century Cure Act passed by the United States Congress in December 2016. The book covers everything from the outline of the initiatives to analysis on the effect on biopharmaceutical research and development. Advanced Statistics in Regulatory Critical Clinical Initiatives provides innovative ways to resolve common challenges in statistical research of rare diseases such small sample sizes and provides guidance for combined use of data. With analysis from regulatory and scientific perspectives this book is an ideal companion for researchers in biostatistics, pharmaceutical development, and policy makers in related fields. Key Features: Provides better understanding of innovative design and analysis of each critical clinical initiatives which may be used in regulatory review/approval of drug development. Makes recommendations to evaluate submissions accurately and reliably. Proposes innovative study designs and statistical methods for oncology and/or rare disease drug development. Provides insight regarding current regulatory guidance on drug development such as gene therapy and rare diseases. |
| fas full analysis set: Pulmonary Disease: New Insights for the Healthcare Professional: 2013 Edition , 2013-07-22 Pulmonary Disease: New Insights for the Healthcare Professional: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Diagnosis and Screening. The editors have built Pulmonary Disease: New Insights for the Healthcare Professional: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Diagnosis and Screening in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Pulmonary Disease: New Insights for the Healthcare Professional: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/. |
| fas full analysis set: Development, assessment, improvement, and standardization of methods in herbal drug research Gunawan Indrayanto, Kornkanok Ingkaninan, Abdul Rohman, 2022-12-08 |
| fas full analysis set: Promoting Mental Health at Work: New Insights and Practical Implications Elisabeth Schramm, Claas Lahmann, Christine Allwang, Kai G. Kahl, Undine E. Lang, 2021-09-14 |
| fas full analysis set: Issues in Flap Surgery Sherif Amr, 2018-04-18 The development of flap surgery parallels the increasing complexity of soft-tissue defects needing reconstruction. Random and pedicled flaps as well as free muscle and fasciocutaneous flaps have helped to reconstruct single soft-tissue defects. The multiplicity of defects needing reconstruction and donor-site morbidity in addition to tailored reconstruction have called for a revision of flap concepts in favor of perforator flaps. Unfortunately, we are faced with increasingly complex reconstructive issues. New reconstructive techniques, such as the Ilizarov method, have made orthopedic reconstruction after high energy and complex trauma possible. Revision surgeries after tumor resection and plastic surgery have brought about soft-tissue defects associated with extensive fibrosis and necrosis. As a result, previously nonsalvageable limbs have been salvaged. The reconstructive surgeons are faced with the following situations: multiple soft-tissue defects, extensive fibrosis, possibility of major vessel loss, and possibility of damage of several perforators. |
| fas full analysis set: Hydrogen-oxygen Inhalation For Treatment Of Covid-19: With Commentary From Zhong Nanshan Kecheng Xu, 2020-10-14 COVID-19 pneumonia is ravaging the world. Faced with the lack of specialized treatment, a novel form of hydrogen-oxygen inhalation therapy has been successfully developed. Molecular hydrogen, a very safe 'physiological gas', has proven to be able to reduce lung damage caused by viruses including COVID-19, improve dyspnea, and promote disease recovery due to its healing biological properties.This book details an innovative form of treatment from theory to practice, and comprehensively discusses the rationality of this new treatment for COVID-19 pneumonia. It is ideal not only for doctors, but also for the general public, as it provides new knowledge and effective treatment and rehabilitation methods to combat this highly infectious disease. |
| fas full analysis set: Immunosuppressive Agents—Advances in Research and Application: 2012 Edition , 2012-12-26 Immunosuppressive Agents—Advances in Research and Application: 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Immunosuppressive Agents. The editors have built Immunosuppressive Agents—Advances in Research and Application: 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Immunosuppressive Agents in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Immunosuppressive Agents—Advances in Research and Application: 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/. |
| fas full analysis set: Cutting-Edge Topics in Dry Eye Disease Kyung Chul Yoon, 2021-06-04 This text presents cutting-edge topics on and the diagnostic and therapeutic approaches for tear film abnormities, including dry eye disease and Meibomian gland dysfunction. A new management algorithm for Meibomian gland dysfunction, therapeutic eye drops and intense pulsed lasers for dry eye disease, and topical and systemic agents for neuropathic ocular pain are proposed in this issue. |
| fas full analysis set: International Pharmaceutical Product Registration Anthony C. Cartwright, Brian R. Matthews, 2016-04-19 Discover the latest ICH news from international experts in the pharmaceutical industry, academia, and regulatory bodies.The recent International Conference on Harmonisation (ICH) revisions of regulatory requirements for quality, nonclinical, and clinical pharmaceutical product registration are the focus of this timely update.This cutting-edge resou |
| fas full analysis set: From Molecular to Modular Tumor Therapy: Albrecht Reichle, 2010-09-09 Presenting a holistic and abstract perspective of tumors, this volume aims to provide personalized diagnostic and therapeutic strategies for the control of metastatic tumor disease. Readers will find ways to record tumor biology that are based on different sciences, in addition to other strategies. |
| fas full analysis set: Strategy and Statistics in Clinical Trials Joseph Tal, 2011-07-14 Delineates the statistical building blocks and concepts of clinical trials. |
| fas full analysis set: Non Pharmacological Therapies in the Management of Osteoarthritis Yves Henrotin, Kim Bennell, Francois Rannou, 2012-03-31 Osteoarthritis is a chronic disease prevalent among the elderly. Its most prominent feature is the progressive destruction of articular cartilage which results in impaired joint motion, severe pain and ultimately disability. Its prevalence and its impact on daily life pose a significant public health problem. Today, a cure for osteoarthritis remains elusive and the management of the disease is largely palliative, focusing on the alleviation of symptoms. Current recommendations include a combination of pharmacological and non-pharmacological treatments. The term “non-pharmacological” includes physical therapy and rehabilitation, but also nutraceuticals. All guidelines on osteoarthritis management highlight the importance of weight loss and physical activity to improve the functional status of patients. A number of alternative therapies are also commonly suggested by physicians and physiotherapists in their daily practice. The efficacy of these therapies is not evidenced by strong clinical trials. This category includes education, information, electrotherapy, ultrasound, electromagnetic field, spa, hydrotherapy, acupuncture, etc. Non Pharmacological Therapies in the Management of Osteoarthritis reviews the clinical relevance of these therapies and the difficulties in conducting high quality trials assessing their efficacy. This e-book presents supportive scientific evidence for their efficacy and explains the mechanism of action of nutraceuticals targeting osteoarthritis. It also includes many example of exercises, mobilization and manipulation techniques directly useful for medical professionals. |
| fas full analysis set: NEUROTHERAPEUTICS IN THE ERA OF TRANSLATIONAL MEDICINE. RICHARD A. SMITH, 2021 |
| fas full analysis set: New insights into renal fibrosis and therapeutic effects of natural products, volume II Dan-Qian Chen, Zhiyong Guo, 2023-04-19 |
| fas full analysis set: Regenerative Medicine Tingting Qiu, Mondher Toumi, 2023-05-23 A comprehensive review of the challenges that exist in patient accessibility to regenerative medicines (RMs), presenting clinical trials, marketing authorization, HTA, pricing, reimbursement, affordability, payment and partnership agreements of RMs and commercialization. Specfically, we investigated how COVID-19 has impacted the RM industry by elaborating on the disruptions it caused but also the new opportunities it brought. The ultimate goal of this work is to make strategic recommendations for manufacturers and decisions-makers on effective strategies to address the above obstacles and facilitate patient access to promising regenerative medicines. FEATURES Regenerative medicine (RM) is an emerging interdisciplinary field aiming to replace or regenerate human cells, tissues, or organs in order to restore normal function. RM holds the promise of revolutionizing treatment in the 21st century. RMs bring new hope for some previously untreatable diseases, as well as holding promise for the treatment of common chronic diseases. Rapid advancements in biotechnology and improved understanding of disease pathophysiology have attracted tremendous interests in the development of RMs. Discusses the high cost of RMs which may challenge the sustainability of healthcare insurers (public and private). |
| fas full analysis set: Essential Reviews in Geriatric Psychiatry Rajesh R. Tampi, Deena J. Tampi, Juan J. Young, Meera Balasubramaniam, Pallavi Joshi, 2022-04-01 This book critically reviews 75 important published papers that influence the practice of geriatric psychiatry. This book will assist anyone who is interested in the care of older adults with psychiatric disorders. It was written by thought leaders who shape the way geriatric psychiatry is currently practiced in the United States. All the major psychiatric disorders in later life are covered including anxiety disorders, bipolar disorders, depressive disorders, neurocognitive disorders, psychotic disorders, sleep disorders, and substance use disorders. It also reviews important studies on suicides in late life and interventional procedures in geriatric psychiatry like the ECT, and also evaluates the adverse effects of psychotropic medications on older adults with psychiatric disorders. The editors of the book along with input from members of the teaching and training committee of the American Association for Geriatric Psychiatry (AAGP) have chosen 75 published papers from the field of geriatric psychiatry that they believe provides the highest knowledge-yield/impact for practicing clinicians and educators in the field of geriatric mental health. The AAGP is a national association that represents and serves its members and the field of geriatric psychiatry. These 75 papers are critically appraised by the members of AAGP using a standardized format and a summary of these papers and their practical application is provided by these experts. This information can be used by anyone who wants to learn about the field of geriatric psychiatry. |
| fas full analysis set: Epidemiology, screening and diagnosis of lung cancer Yutong He, Xue Qin Yu, Chen Wanqing, Jackilen Shannon, Yingsong Lin, 2023-05-08 |
| fas full analysis set: Advances in Antiviral Drug Design E. De Clercq, 2003-12-17 The fourth volume of Advances in Antiviral Drug Design is keeping up with the recent progress made in the broad field of antiviral drug research and encompasses six specific directions that have opened new avenues for the treatment of HIV and other virus infections.First, as the introductory chapter, the different new anti-HIV agents that are now in preclinical or clinical development are reviewed by E. De Clercq. This includes new NRTIs, NNRTIs and PIs, but also HIV entry/fusion inhibitors as well as integrase inhibitors, and some of these agents, such as the NRTI emtricitabine [(-)FTC] and the PI atazanavir, may soon be licensed for clinical use.Second, high expectations are vested in the potential therapeutic usefulness of inhibitors of HIV integration, a point of no return in the life cycle of HIV, and this approach is highlighted by D.J. Hazuda and S.D. Young.Third, as all currently available PIs can be described as peptidomimetic, and, therefore, expected to demonstrate overlapping virus-drug resistance and side effect profiles, it would be interesting to see how a non-peptidic protease inhibitor such as tipranavir behaves, and this is covered by D. Mayers, K. Curry, V. Kohlbrenner and S. McCallister.Fourth, neuraminidase inhibitors such as zanamivir (that has to be inhaled) and oseltamivir (that can be administered via the oral route) have gained a definitive status as antiviral drugs useful for both therapy and prophylaxis of influenza A and B virus infections; as they target a specific influenza viral enzyme, neuraminidase (or sialidase), they may be expected to block newly emerging influenza viruses as well, and the design of neuraminidase inhibitors has received due attention of H. Jin and C.U. Kim.Fifth, while the major current efforts in antiviral drug development have shifted from herpesviruses towards HIV and hepatitis viruses [hepatitis B virus (HBV), hepatitis C virus (HCV)], it is interesting to note that by switching from the classical five-membered sugar or acyclic nucleoside strategy, J. Wang, M. Froeyen and P. Herdewijn have gone upstream in designing six-membered carbocyclic nucleosides as potential anti-herpesvirus agents.Sixth, following up on the nucleotide prodrug strategy introduced above under ix, to deliver the biologically active nucleotides inside the cells, C. Meier has elaborated on a particular class of such pronucleotides, namely that of the cyclosaligenyl pronucleotides, an approach that should have far reaching implications for compounds effective against HIV, HBV and other viruses.The six topics covered in this fourth volume of Advances in Antiviral Drug Design are in the front line of the present endeavors towards the design and development of new therapeutic agents for virus infections. They pertain to the combat against three of the most important viral pathogens of current times: HIV, HBV, influenza virus and herpesviruses. |
| fas full analysis set: Biomarkers and Immunotherapy of Hepatic-Biliary-Pancreatic Cancers Yunfei Xu, Hongda Liu, Xuexong Gu, Zheng Gong, 2024-02-29 Hepatic-biliary-pancreatic cancers, mainly including hepatocellular carcinoma, cholangiocarcinoma, gallbladder cancer, are highly aggressive malignancies with few treatment options and poor prognoses. Effects of the traditional systemic treatments such as chemotherapy and radiotherapy, are quite limited to hepatic-biliary-pancreatic cancers. For the patients who suffer from hepatic-biliary-pancreatic cancer and lose the opportunity of radical surgery, few targeted drugs are available. Even for the drugs in clinical trial, potential drug targets and prognostic biomarkers for hepatic-biliary-pancreatic cancer are less studied compared to other common cancers such as lung cancer. Prognostic biomarker study is the initiation to explore new drug targets and revelation of the underlying mechanisms of tumor progression. |
| fas full analysis set: Instructional Course Lectures: Volume 71 Eric Strauss, Brian Galinat, 2022-01-10 Developed in partnership with the American Academy of Orthopaedic Surgeons (AAOS) and edited by Eric J. Strauss, MD, FAAOS (editor) and Brian J. Galinat, MD, MBA, FAAOS (assistant editor), Instructional Course Lectures, Volume 71 offers solutions for the most current issues and challenges faced at all stages of your career. Filled with current, clinically relevant presentations and approaches, the book broadens your treatment options with experience-based solutions from today’s most respected surgeons and specialty experts. Based on selected Instructional Course Lectures presented at the AAOS Annual Meeting 2021 in San Diego Lead innovation and raise the standard of care in your operating room with new techniques and proven practical approaches. Expand and refresh your general orthopaedic, specialty, and practice knowledge Learn new approaches and surgical techniques from thought leaders Update your action plans for rehabilitative care with expert insights Review new techniques for solving the tough challenges you encounter in your practice every day Chapters are abundantly illustrated with radiographs, drawings, and intraoperative photographs. Some chapters are enhanced with video that bring the techniques to life |
| fas full analysis set: Neurorehabilitation In Neurotrauma: Treating Traumatic Brain and Spinal Cord Injuries Fernando Zanela Arêas, Hang Jin Jo, Guilherme Peixoto Tinoco Arêas , Lora Watts, 2024-09-23 Traumatic Brain Injuries (TBI) and Spinal Cord Injuries (SCI) can have long-term adverse effects on populations, including an increased risk of mortality, enduring disabilities and other long-term health problems. Both of these injuries affect large numbers of people, with between 250,000 and 500,000 people affected by a spinal cord injury every year, according to the WHO, and between 27 and 69 million people estimated to have been affected by a Traumatic Brain Injury worldwide. The effects of such injuries are far reaching and include loss of motor functions, impaired neurotransmission, neuroinflammation, apoptotic cell death (among others) and can cause persisting cognitive degradation and impairments. However, there exist a number of rehabilitative and regenerative processes and methods that help to restore motor functions and limit enduring disabilities within those affected by TBI and SCI, principally to facilitate neuroplasticity. |
Home - Federation of American Scientists
FAS envisions a world where cutting-edge science, technology, ideas and talent are deployed to solve the biggest challenges of our time. We embed science, technology, innovation, and …
Fetal Alcohol Syndrome: Symptoms, Causes, Treatments - WebMD
May 29, 2024 · What Is Fetal Alcohol Syndrome? Fetal alcohol syndrome (FAS) is the most severe fetal alcohol spectrum disorder. These are a group of conditions present at birth that …
CAMP - A FASD Community
Here at CAMP - A FASD Community, we are pleased to offer our annual, week-long, flagship program for children and adolescents ages 9 - 18 diagnosed with, or suspected to have …
Fetal Alcohol Syndrome (FAS): Symptoms, Causes & Treatment
A permanent condition, fetal alcohol syndrome (FAS) happens when a woman consumes any amount of alcohol during a pregnancy. Alcohol use during pregnancy can interfere with the …
Food Export Association of the Midwest USA - Wikipedia
Food Export Association of the Midwest USA (Food Export-Midwest) is a non-profit organization created in 1969 as a cooperative effort between 13 Midwestern state agricultural promotion …
Fetal alcohol syndrome in adults: Signs and more
Dec 18, 2023 · Fetal alcohol syndrome (FAS) is a form of fetal alcohol spectrum disorder (FASD). It can occur if a fetus is exposed to alcohol in the womb. FAS can cause learning and …
Fetal alcohol spectrum disorder - Wikipedia
Fetal alcohol spectrum disorders (FASDs) are a group of conditions that can occur in a person who is exposed to alcohol during gestation. [1] . FASD affects 1 in 20 Americans, but is highly …
Illinois Foot and Ankle Specialists PC. – (773) 763-6655
Welcome to IL Foot and Ankle Specialists PC. We are committed to provide the highest standard of quality of podiatric care, using most effective ways to diagnose and treat your ankle and foot …
Chicago FASD - The Center for Neurobehavioral Guidance
Fetal Alcohol Spectrum Disorders (FASD) is an umbrella term that includes a range of disabilities associated with fetal alcohol exposure. FASD can include physical, mental, behavioral and/or …
Federation of American Scientists :: Publications and Reports
Jan 27, 2014 · FAS maintains multiple blogs on topics ranging from government secrecy to national security concerns. FAS reports are available online in PDF format.
